Dr. Michael Coleman has more than 29 years of experience as a research scientist and executive in the biotechnology, medical device, and pharmaceutical industries. Dr. Coleman has extensive experience in translational research and has led the successful development and commercialization of biologic drugs, including advanced therapies, and medical devices in compliance with US FDA and EU regulations.

Dr. Singh is the CSO and Founder of Vasculonics. He has more than 25 years of drug development experience at Eli Lilly and Upjohn where he led multiple drug discovery projects in cardiovascular disease, stroke, and vascular complications of diabetes. Dr. Singh has served as CSO and VP Research at St. Joseph’s Translational Research Institute in Atlanta and was the Founding Director of the Indiana Center for Biomedical Innovation.

Jon has been CEO of 3 previous biotech companies all moving forward and doing well. He was COO of Jubilant Innovation, the venture arm of Jubilant Life Sciences in India, and was 28 years at Eli Lilly, where he launched 5 drugs into the market and did 40 deals in business development, buying products and technologies that Lilly wanted to add to its portfolio. Jon is a published author (Business of Healthcare Innovation) and a Wharton MBA.